# Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing

**Authors:** Xuemei Li, Claudia Schirra, Marie-Louise Wirkner, Szu-Min Tu, Chin-Hsin Lin, Meltem Hohmann, Yuan Gu, Llipsy Santiago, Julian Pardo, Iñaki Arretxe, Nadia Alawar, Abed Alrahman Chouaib, Ute Becherer, Po-Hsien Lee, Hao-Jen Hsu, Matthias W. Laschke, Cosima T. Baldari, Michael L. Dustin, Jens Rettig, Elmar Krause, Hsin-Fang Chang

PMC · DOI: 10.1038/s41423-026-01391-1 · 2026-03-04

## TL;DR

This study reveals that IFNγ is stored in cytotoxic granules and released with granzyme B to enhance T cell killing of tumor cells.

## Contribution

The discovery of lytic IFNγ stored in cytotoxic granules and its role in CTL-mediated cytotoxicity is novel.

## Key findings

- Lytic IFNγ is stored in granzyme B⁺ cytotoxic granules and released at the immunological synapse.
- IFNγ enhances CTL-mediated tumor cell death via the IFNγ–STAT1–caspase-3 pathway.
- Nonpolarized IFNγ secretion occurs from MVBs or small vesicles during prolonged synapse engagement.

## Abstract

Cytotoxic T lymphocytes (CTLs) eliminate target cells by forming immunological synapses and releasing effector molecules, including interferon gamma (IFNγ). However, how IFNγ contributes to cytotoxicity remains unclear. Here, we identify a subset of IFNγ stored within granzyme B⁺ cytotoxic granules (CGs) in activated mouse and human CTLs, which we term lytic IFNγ. This CG-associated IFNγ represents the primary pool released in a polarized manner at the immunological synapse together with canonical lytic molecules. Lytic IFNγ is present in tumor-infiltrating CTLs and is cosecreted with granzyme B (GzmB) in both soluble form and as part of supramolecular attack particles (SMAPs). Functional assays indicate that IFNγ contributes to CTL-mediated tumor cell death by acting in concert with granzyme B and perforin to increase cytotoxicity and promote apoptosis via the IFNγ–STAT1–caspase-3 pathway. CTLs lacking the vesicle priming factor Munc13-4 exhibit impaired release of both CGs and early-phase IFNγ. However, prolonged synapse engagement restores IFNγ secretion at distal membrane sites, revealing a second, nonpolarized IFNγ pool. Consistently, endogenous IFNγ is detected in both CG-enriched and multivesicular body (MVB)-enriched fractions. We propose that while lytic IFNγ is released from CGs at the synapse to directly promote target cell killing, nonpolarized IFNγ secretion originates from MVBs or small vesicles during sustained activation. Together, these findings reveal a previously unrecognized mechanism of IFNγ storage and release, establishing lytic IFNγ as a critical effector component of CTL cytotoxicity and antitumor immunity.

## Linked entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458], GZMB (granzyme B) [NCBI Gene 3002], STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772], Casp3 (caspase 3) [NCBI Gene 12367], UNC13D (unc-13 homolog D) [NCBI Gene 201294]
- **Proteins:** PRF1 (perforin 1)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, UNC13D (unc-13 homolog D) [NCBI Gene 201294] {aka HLH3, HPLH3, Munc13-4}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}
- **Diseases:** cytotoxicity (MESH:D064420), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035909/full.md

---
Source: https://tomesphere.com/paper/PMC13035909